Steven M. Paul, MD, is affiliated with Karuna Therapeutics in Boston, Massachusetts. His published work focuses on schizophrenia and schizoaffective disorders, including adjunctive treatments targeting multiple mechanisms and the antipsychotic efficacy of KarXT (Xanomeline–Trospium). Dr. Paul has contributed to clinical research analyzing symptom response and treatment outcomes in phase 2 studies. His frequent collaborators include Alan Breier, Andrew C. Miller, Bruce J. Kinon, Carol Tamminga, and Peter J. Weiden.
1 Read counts for articles published before 2020 may include some non-human traffic.
2 Citation counts provided by Crossref.
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
